

Position Statement



Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO)

Min Chul Choi,¹ Myong Cheol Lim,² Dong Hoon Suh,³ Yong Jung Song,⁴ Tae-Joong Kim,⁵ Suk-Joon Chang,⁶ Jae-Weon Kim,⁷ on the behalf of the Korean Society of Gynecologic Oncology

¹Comprehensive Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

²Center for Uterine Cancer, National Cancer Center, Goyang, Korea

³Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

⁴Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea

⁵Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁶Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea

⁷Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea

OPEN ACCESS

Received: Mar 9, 2016

Accepted: Mar 19, 2016

Correspondence to

Myong Cheol Lim

Center for Uterine Cancer and Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea.
E-mail: gynlim@gmail.com

Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This statement sets out the position of the Korean Society of Gynecologic Oncology regarding the assessment of genetic tests on women with peritoneal, ovarian, and fallopian tubal (POFT) cancers and their families.

Two high susceptibility genes (*BRCA1* and *BRCA2*) have been identified for hereditary breast and ovarian cancer (HBOC) and these genes normally function as tumor suppressor genes [1,2]. Women with *BRCA1* or *BRCA2* mutations have a 39% or 11% (1.3% in normal population) cumulative risk for ovarian cancer by the age of 70 years, respectively [3]. The prevalence of *BRCA* mutations in Korean women with POFT cancers regardless of family history has been reported to be as high as 23.8% to 25.7% [4,5]. The substantial frequency of *BRCA* mutations in the Korean population is expected to be higher than that reported in previous studies, because of the limitations involved in confirming the exact family history in Korea [6]. Approximately 15% cases of ovarian cancer are due to germline genetic mutations and the prevalence of peritoneal and fallopian tubal cancers is higher than that of ovarian cancer [7]. Studies concerning other genes (*PTEN*, *TP53*, *BRIP1*, and *RAD51D*) known to cause HBOC are also in progress [8-11], but it is difficult to apply those genes clinically in Korea at the present.

Genetic counseling and clinical genetic testing allow physicians to precisely identify women who are at substantial risk for POFT and breast cancer. For these individuals, surveillance and risk reducing strategies can be instituted to reduce the risk to them and their family. If one of the parents harbors the *BRCA* mutation, the prevalence of *BRCA* mutation in each child is found

ORCID

Min Chul Choi
<http://orcid.org/0000-0003-4509-6731>
 Myong Cheol Lim
<http://orcid.org/0000-0001-8964-7158>
 Dong Hoon Suh
<http://orcid.org/0000-0002-4312-966X>
 Yong Jung Song
<http://orcid.org/0000-0002-6103-2466>
 Tae-Joong Kim
<http://orcid.org/0000-0002-9693-9164>
 Suk-Joon Chang
<http://orcid.org/0000-0002-0558-0038>
 Jae-Weon Kim
<http://orcid.org/0000-0003-1835-9436>

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

to be 50%. The candidates for *BRCA* genetic tests focusing on the proband are patients with POFT cancers and their families, especially first degree relatives (parents, siblings, and offspring).

The recommendations of the Korean Society of Gynecologic Oncology for *BRCA* genetic testing are follows:

- POFT cancers or breast cancer diagnosed with the first or second degree relative with POFT or breast cancer
- Epithelial ovarian cancer, fallopian tubal cancer, or peritoneal cancer
- A personal history of both POFT and breast cancer
- Early onset breast cancer (diagnosed ≤ 40 years)
- Bilateral breast cancer
- Multiple organ cancers including breast cancer
- Male breast cancer
- First degree relatives of an individual with a known *BRCA1* or *BRCA2* mutation

A germline mutation in *BRCA* was associated with improved 5-year overall survival among patients with epithelial ovarian cancer [12]. Poly (ADP-ribose) polymerase inhibitors (niraparib, olaparib, rucaparib, or veliparib) can be used in patients with POFT cancer harboring *BRCA* mutations and better treatment options are promising [13,14].

The opportunity to provide tailored screening and risk reducing strategies such as surveillance, chemoprevention and risk-reducing surgery may reduce the morbidity and mortality in *BRCA* carriers.

PRACTICAL INFORMATION

There are several programs to calculate the prevalence of *BRCA* mutations considering the clinical environment and family history of individuals.

- <http://www.myriadpro.com/brca-risk-calculator/calc.html>
- <http://www.ibreast.kr/BRCA/BRCA.html> (Korean model)
- <http://www4.utsouthwestern.edu/breasthealth/cagene>

The probability of harboring the *BRCA* genetic mutation according to the clinical environment is as follows:

- The prevalence of *BRCA* mutation in high grade serous epithelial ovarian cancer is approximately 23% to 40% [15,16].
- The prevalence of *BRCA* mutation in Korean ovarian cancer patients with a family history of ovarian cancer in a first degree relative is approximately 63% [17].
- The prevalence of *BRCA* mutation in Korean ovarian cancer patients with a family history of breast cancer in a first degree relative is approximately 21% [17].
- The prevalence of *BRCA* mutation in Korean ovarian cancer patients with a family history of ovarian or breast cancer in a first degree relative is approximately 33% to 61% [16,17].
- The prevalence of *BRCA* mutation in Korean ovarian cancer patients without a family history of ovarian cancer in a first degree relative is approximately 9% to 13% [16,17].

For *BRCA* carriers, the need for strict adherence to screening schedules for peritoneal, ovarian, and fallopian tubal (POFT) cancers such as transvaginal sonograms or serum CA-125

tests every 4 months and frequent screening for POFT cancers might offer a better chance for early stage detection [18].

Transvaginal ultrasound and serum CA125 tests can be performed when the prevalence of POFT cancer is predicted to be more than 10% as follows [18].

1. Known carriers of one of the predisposing genes (BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS1, or PMS2).
2. Families with two or more individuals suffering from POFT cancer who were first-degree relatives.
3. Families with one individual suffering from POFT cancer and one individual with breast cancer diagnosed at age <50 years who were first-degree relatives.
4. Families with one individual suffering from POFT cancer and two individuals with breast cancer diagnosed at age <60 years who were first-degree relatives.
5. Families with three individuals suffering from colorectal cancer, at least one of whom was diagnosed at age <50 years as well as one individual suffering from POFT cancer, and all of these individuals were connected by first-degree relationships.

If the patients are clinically suspected of POFT cancer, they should be assessed for a family history of POFT cancer and breast cancer. Genetic counseling and genetic testing are provided after pathological diagnosis. BRCA carriers should be counseled about risk-reducing bilateral salpingo-oophorectomy, ideally between 35 to 40 years and upon completion of child-bearing or in an individualized manner based on the earliest age of onset of ovarian cancer in the family.

Even in families with the BRCA mutation, the risk of developing POFT cancer or breast cancer in a woman under the age of 21 years is extremely low. Therefore, and considering the potential negative impact of genetic testing, the Korean Society of Gynecologic Oncology panel does not recommend genetic testing for women under the age of 21 years for hereditary breast and ovarian cancer in the absence of a family history of early-onset cancer.

REFERENCES

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66-71.
[PUBMED](#) | [CROSSREF](#)
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789-92.
[PUBMED](#) | [CROSSREF](#)
3. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA* 2006;295:1379-88.
[PUBMED](#) | [CROSSREF](#)
4. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. *J Cancer Res Clin Oncol* 2009;135:1593-9.
[PUBMED](#) | [CROSSREF](#)
5. Choi MC, Heo JH, Jang JH, Jung SG, Park H, Joo WD, et al. Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations. *Int J Gynecol Cancer* 2015;25:1386-91.
[PUBMED](#) | [CROSSREF](#)
6. Son Y, Lim MC, Seo SS, Kang S, Park SY. Completeness of pedigree and family cancer history for ovarian cancer patients. *J Gynecol Oncol* 2014;25:342-8.
[PUBMED](#) | [CROSSREF](#)

7. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolny F, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222-7.
[PUBMED](#) | [CROSSREF](#)
8. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-7.
[PUBMED](#) | [CROSSREF](#)
9. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol* 2009;27:1250-6.
[PUBMED](#) | [CROSSREF](#)
10. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet* 2011;43:1104-7.
[PUBMED](#) | [CROSSREF](#)
11. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Breast Cancer Susceptibility Collaboration (UK). Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet* 2011;43:879-82.
[PUBMED](#) | [CROSSREF](#)
12. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382-90.
[PUBMED](#) | [CROSSREF](#)
13. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol* 2014;15:852-61.
[PUBMED](#) | [CROSSREF](#)
14. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. *Gynecol Oncol* 2014;133:362-9.
[PUBMED](#) | [CROSSREF](#)
15. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011;474:609-15.
[PUBMED](#) | [CROSSREF](#)
16. Choi MC, Heo JH, Jang JH, Jung SG, Park H, Joo WD, et al. Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations. *Int J Gynecol Cancer* 2015;25:1386-91.
[PUBMED](#) | [CROSSREF](#)
17. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. *J Cancer Res Clin Oncol* 2009;135:1593-9.
[PUBMED](#) | [CROSSREF](#)
18. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. *J Clin Oncol* 2013;31:49-57.
[PUBMED](#) | [CROSSREF](#)